Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 12, 2021updated 16 Apr 2021 2:59pm

Zentalis and GSK sign clinical collaboration agreement

Zentalis Pharmaceuticals has announced a clinical collaboration agreement to evaluate the combination of its ZN-c3 and GlaxoSmithKline’s (GSK) ZEJULA (niraparib) in advanced epithelial ovarian cancer patients.

Zentalis Pharmaceuticals has announced a clinical collaboration agreement to evaluate the combination of its ZN-c3 and GlaxoSmithKline’s (GSK) ZEJULA (niraparib) in advanced epithelial ovarian cancer patients.

ZEJULA is an FDA and EMA-approved oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor.

At present, Zentalis is conducting clinical studies with its oral WEE1 inhibitor product candidate, ZN-c3, as a monotherapy and in combination with certain standard of care therapies.

Zentalis Pharmaceuticals chairman and CEO Dr Anthony Sun said: “This clinical collaboration and supply agreement with GSK allows us to investigate the broader potential of our WEE1 inhibitor when used as part of a combination treatment with niraparib, a PARP inhibitor.

“As demonstrated in our preclinical studies, ZN-c3 is designed to have significant advantages over other investigational WEE1 inhibitor therapies. We believe this combination has the potential to meaningfully improve the outcomes for patients with ovarian cancer.”

Under the non-exclusive collaboration terms, Zentalis will perform the study with GSK providing all required doses of niraparib. Complete ownership of ZN-c3 would be maintained by Zentalis.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

WEE1 plays a key role in cellular regulation and repair and its inhibition causes dysregulation of DNA replication and subsequently induces apoptosis.

Based on these complementary mechanisms of action, the use of WEE1 and PARP inhibitors is expected to potentially have synergistic anti-tumour activity.

Zentalis is currently conducting a Phase I/II clinical trial of ZN-c3 in patients with advanced solid tumours and a Phase Ib trial evaluating ZN-c3 in combination with chemotherapy in advanced ovarian cancer patients.

The company also plans to initiate a Phase I/II trial in combination with GSK’s niraparib for advanced ovarian cancer patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU